We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial

MedXY Editorial Team•Nov 14, 2025•news
pharmacogenomicstreatment-resistant depression

Highlight

– In ENLIGHTEN, ANK3-positive patients with treatment‑resistant depression (TRD) randomized to liafensine (1 or 2 mg daily) had a statistically and clinically significant greater reduction in MADRS score at day 42 than placebo (mean difference −4.4 points, 95% CI −7.6 to −1.3; P = .006).

– This is the first prospective, randomized, biomarker‑guided clinical trial in psychiatry reporting successful enrichment of responders using a genetic marker (ANK3).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Harnessing Genomics for Precision Prevention in Psychiatry: Opportunities and ChallengesGenomic testing holds promise for guiding preventive strategies in psychiatry, particularly in high-risk and clinically uncertain contexts; however, current evidence supports targeted rather than universal approaches.Sep 2, 2026Impact of CYP2C19 Polymorphisms on Medical and Surgical Management of GERD: Implications for Personalized TherapyA study reveals a higher prevalence of rapid CYP2C19 metabolizer phenotypes in GERD patients undergoing surgery versus medical therapy, supporting tailored proton pump inhibitor dosing and timely surgical referral.Aug 25, 2026Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical TrialPsilocybin-assisted psychotherapy showed promising but inconclusive antidepressant effects in treatment-resistant depression, with notable acute adverse events and safety concerns.May 18, 2026Precision Medicine Fails to Improve Postoperative Pain: Insights from the CYP2D6-Guided Opioid Trial
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
A randomized clinical trial demonstrates that while CYP2D6 genotyping significantly shifts opioid prescribing patterns for poor and intermediate metabolizers, it does not improve pain control or reduce opioid consumption within the context
Feb 23, 2026
Ketogenic Diet Shows Modest Short-Term Benefits in Treatment-Resistant Depression: A Critical Review of New Clinical Trial EvidenceA randomized clinical trial finds that a 6-week ketogenic diet provides modest antidepressant effects for treatment-resistant depression compared to a healthy control diet, though long-term clinical relevance and impact on secondary outcomeFeb 5, 2026
Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic FrontierA phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.Oct 7, 2025